These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36175196)

  • 1. Writing dosage of Piperacillin Tazobactam in susceptibility reports: An idea worth trying ??
    Hada V; Singh P; Mohanty A
    Indian J Med Microbiol; 2023; 42():110-111. PubMed ID: 36175196
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro susceptibility of Acinetobacter baumannii to biapenem, piperacillin/tazobactam and thirteen other antimicrobial agents.
    Simor AE; Louie L; Louie M
    Eur J Clin Microbiol Infect Dis; 1994 Jun; 13(6):521-3. PubMed ID: 7957281
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical implications of revised piperacillin-tazobactam breakpoints in CLSI M-100 S32.
    Dash D; Rai S
    Indian J Med Microbiol; 2023; 42():108-109. PubMed ID: 36241530
    [No Abstract]   [Full Text] [Related]  

  • 4. Letter responding to performance of updated
    Patel JB; Duncan E; Cullen S
    J Clin Microbiol; 2023 Nov; 61(11):e0049723. PubMed ID: 37823655
    [No Abstract]   [Full Text] [Related]  

  • 5. In vitro and in vivo evidence discourages routine testing and reporting of piperacillin/tazobactam susceptibility of Elizabethkingia species.
    Tan MC; Huang YC; Chen PJ; Huang WC; Hsu SY; Wang HY; Liou CH; Sun JR; Lauderdale TY; Kuo SC
    J Antimicrob Chemother; 2024 Jan; 79(1):200-202. PubMed ID: 37850648
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of four antimicrobial susceptibility testing methods to determine the in vitro activities of piperacillin and piperacillin-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa.
    Karlowsky JA; Weaver MK; Thornsberry C; Dowzicky MJ; Jones ME; Sahm DF
    J Clin Microbiol; 2003 Jul; 41(7):3339-43. PubMed ID: 12843088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lessons learned from an external quality assurance program in applying CLSI interpretive criteria for reporting piperacillin/tazobactam susceptibility.
    Veeraraghavan B; Bakthavatchalam YD; Sahni RD
    Indian J Med Microbiol; 2024; 48():100552. PubMed ID: 38442789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The sensitivity of clinical isolates of anaerobic species to piperacillin-tazobactam and other antimicrobial agents.
    Namavar F; Severin WP; Stobberingh E; Smeets T; MacLaren DM
    J Antimicrob Chemother; 1994 Sep; 34(3):415-9. PubMed ID: 7829416
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative in vitro activity of piperacillin, piperacillin-sulbactam and piperacillin-tazobactam against nosocomial pathogens isolated from intensive care patients.
    Frank U; Mutter J; Schmidt-Eisenlohr E; Daschner FD
    Clin Microbiol Infect; 2003 Nov; 9(11):1128-32. PubMed ID: 14616732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deconstructing the 2023 Clinical and Laboratory Standards Institute Revised Piperacillin-Tazobactam Breakpoints Against Pseudomonas aeruginosa.
    Tamma PD; Harris PNA; Mathers AJ; Wenzler E; Humphries RM
    Clin Infect Dis; 2023 May; 76(10):1868-1870. PubMed ID: 36625154
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro susceptibility of multi-drug resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolated from clinical specimens at Bugando Medical Centre, Tanzania to Piperacillin-Tazobactam.
    Petro D; Mushi MF; Moremi N; Iddi S; Mirambo M; Seni J; Mshana SE
    Tanzan J Health Res; 2014 Jan; 16(1):54-7. PubMed ID: 26867273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility survey of piperacillin alone and in the presence of tazobactam.
    Acar JF; Goldstein FW; Kitzis MD
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():23-8. PubMed ID: 8383653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comment on: Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against Klebsiella pneumoniae.
    Giry M; Sarfati S; Pestel-Caron M; Wils J; Lamoureux F; Alexandre K
    J Antimicrob Chemother; 2022 Sep; 77(10):2892-2894. PubMed ID: 35538913
    [No Abstract]   [Full Text] [Related]  

  • 14. Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections.
    Johnson DM; Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2002 May; 43(1):49-60. PubMed ID: 12052629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus Isolates and vancomycin-intermediate S. aureus isolates in vitro.
    Dilworth TJ; Sliwinski J; Ryan K; Dodd M; Mercier RC
    Antimicrob Agents Chemother; 2014; 58(2):1028-33. PubMed ID: 24277036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International dissemination of Escherichia coli strains with discrepant behaviour in phenotypic antimicrobial susceptibility tests.
    Creely D; Zambardi G; van Belkum A; Dunne WM; Peyret M; Gayral JP; Shortridge D; Shubert C
    Eur J Clin Microbiol Infect Dis; 2013 Aug; 32(8):997-1002. PubMed ID: 23397255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
    Xiao YH; Hu YJ
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative susceptibility profile of piperacillin/tazobactam against anaerobic bacteria.
    Appelbaum PC
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():29-38. PubMed ID: 8383654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in-vitro activity of piperacillin-tazobactam against recent clinical isolates, a Dutch national multicentre study.
    Stobberingh EE; Maclaren DM; Schmitz PI
    J Antimicrob Chemother; 1994 Nov; 34(5):777-83. PubMed ID: 7706173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations.
    Liu Q; Rand K; Derendorf H
    Int J Antimicrob Agents; 2004 May; 23(5):494-7. PubMed ID: 15120729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.